**PATENT ASSIGNMENT**

Electronic Version v1.1  
Stylesheet Version v1.1

<table>
<thead>
<tr>
<th>SUBMISSION TYPE:</th>
<th>CORRECTIVE ASSIGNMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>NATURE OF CONVEYANCE:</td>
<td>Corrective Assignment to correct the name of the assignor from 'EPITECH SA' to --EPISOURCE SA--. previously recorded on Reel 016862 Frame 0490. Assignor(s) hereby confirms the entire right, title and interest for the United States and in all countries..</td>
</tr>
</tbody>
</table>

**CONVEYING PARTY DATA**

<table>
<thead>
<tr>
<th>Name</th>
<th>Execution Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPISOURCE SA</td>
<td>12/15/2004</td>
</tr>
</tbody>
</table>

**RECEIVING PARTY DATA**

<table>
<thead>
<tr>
<th>Name:</th>
<th>DFB PHARMACEUTICALS, INC.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Street Address:</td>
<td>3909 Hulen Street</td>
</tr>
<tr>
<td>City:</td>
<td>Fort Worth</td>
</tr>
<tr>
<td>State/Country:</td>
<td>TEXAS</td>
</tr>
<tr>
<td>Postal Code:</td>
<td>76107</td>
</tr>
</tbody>
</table>

**PROPERTY NUMBERS Total: 7**

<table>
<thead>
<tr>
<th>Property Type</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Number:</td>
<td>10655435</td>
</tr>
<tr>
<td>Patent Number:</td>
<td>6548058</td>
</tr>
<tr>
<td>Patent Number:</td>
<td>6730513</td>
</tr>
<tr>
<td>Patent Number:</td>
<td>7014849</td>
</tr>
<tr>
<td>Patent Number:</td>
<td>7144729</td>
</tr>
<tr>
<td>Patent Number:</td>
<td>5968546</td>
</tr>
<tr>
<td>Patent Number:</td>
<td>6673603</td>
</tr>
</tbody>
</table>

**CORRESPONDENCE DATA**

Fax Number: (512)536-4598  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
Phone: 512-536-3035  
Email: jbyron@fulbright.com  
Correspondent Name: Mark B. Wilson  
Address Line 1: 600 Congress Ave.
<table>
<thead>
<tr>
<th>ATTORNEY DOCKET NUMBER:</th>
<th>DFBP</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAME OF SUBMITTER:</td>
<td>Mark B. Wilson</td>
</tr>
</tbody>
</table>

Total Attachments: 8
source=DFBP#page1.tif
source=DFBP#page2.tif
source=DFBP#page3.tif
source=DFBP#page4.tif
source=DFBP#page5.tif
source=DFBP#page6.tif
source=DFBP#page7.tif
source=DFBP#page8.tif
ASSIGNMENT

EpiSource SA, a corporation organized under the laws of Switzerland, having principal offices at 1 Rue de Sébeillon, 1004 Lausanne, Switzerland (the ASSIGNOR), the undersigned, for good and valuable consideration, the receipt of which is hereby acknowledged, hereby assigns, sells and transfers to DFB Pharmaceuticals, Inc., a corporation organized under the laws of Texas, having principal offices at 3909 Hulen Street, Fort Worth, Texas 76107, and its successors, assigns and legal representatives, all hereinafter referred to as the ASSIGNEE:

(1) the entire right, title and interest for the United States and in all countries, in and to any and all inventions, discoveries and applications which are disclosed in the patents and applications for patents as listed in Schedule A, including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of the ASSIGNEE, its designee, or in the name of EpiSource SA at the ASSIGNEE, or its designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patents which may issue thereon in the United States or in any country, and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; and (4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

EpiSource SA hereby authorizes and requests the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to the ASSIGNEE of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by EpiSource SA had this assignment, sale and transfer not been made.

EpiSource SA agrees, at any time, upon the request of the ASSIGNEE, to execute and to deliver to the ASSIGNEE any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries, or applications and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.

EpiSource SA further agrees at any time to execute and to deliver upon request of the ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of the ASSIGNEE under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

EpiSource SA hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.
EpiSource SA further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.
For EpiSource SA:

Date: December 15, 2004

Signature of:
Title: Director
EpiSource SA

IN WITNESS WHEREOF,

Signature of witness:

this 15th day of December, 2004

Date of signing

IN WITNESS WHEREOF,

Signature of witness:

this 15th day of December, 2004

Date of signing
For DFB Pharmaceuticals, Inc.:

Date: __________________________

Signature of:
Title: Chief Scientific Officer
DFB Pharmaceuticals, Inc.

IN WITNESS WHEREOF,

[Signature of witness]

this 15th day of December 2004
Date of signing

IN WITNESS WHEREOF,

[Signature of witness]

this 15th day of December 2004
Date of signing
SCHEDULE A

1. 17811-014-004 (M-14 AU)
    Australian Patent Application No. 60098/00
    Entitled: “Improved Keratinocyte Culture and Uses Thereof”

2. 17811-014-008 (M-14 CA)
    Canadian Patent Application No. 2,379,949
    Entitled: “Improved Keratinocyte Culture and Uses Thereof”

3. 17811-014-019 (M-14 EP)
    European Patent Application No. 00946228.4
    Entitled: “Improved Keratinocyte Culture and Uses Thereof”

4. 17811-014-032 (M-14 JP)
    Entitled: “Improved Keratinocyte Culture and Uses Thereof”

5. 17811-014-061 (M-14 WO)
    PCT Patent Application No. PCT/IB00/01076
    Entitled: “Improved Keratinocyte Culture and Uses Thereof”

6. 17811-014 (M-14)
    United States Patent No. 6,548,058
    Entitled: “Keratinocyte Culture and Uses Thereof”

7. 17811-014 CIP (M-14 CIP)
    United States Patent No. 6,730,513
    Entitled: “Keratinocyte Culture and Uses Thereof”
8. 17811-014 NATL (M-14 NATL)  
Entitled: “Improved Keratinocyte Culture and Uses Thereof”

9. 17811-015 (M-15)  
United States Patent No. 5,968,546  
Entitled: “Keratinocyte Culture from Precursor Cells”

10. 17811-017 (M-17)  
United States Patent No. 6,673,603  
Entitled: “Cell Paste Comprising Keratinocytes and Fibroblasts”

11. 17811-017 CIP (M-17 CIP)  
United States Patent Application No. 10/324,257  
Entitled: “Methods and Compositions for Tissue Regeneration”

12. 17811-017-032 CIP (M-17 CIP JP)  
Entitled: “Methods and Compositions for Tissue Regeneration”

13. 17811-017-061 CIP (M-17 CIP WO)  
PCT Patent Application No. PCT/US03/27888  
Entitled: “Methods and Compositions for Tissue Regeneration”

14. 17811-017-004 (M-17 AU)  
Australian Patent Application No. 2001286952  
Entitled: “Methods and Compositions for Tissue Regeneration”

15. 17811-017-008 (M-17 CA)  
Canadian Patent Application No. 2426107  
Entitled: “Methods and Compositions for Tissue Regeneration”
16. 17811-017-019 (M-17 EP)
   European Patent Application No. 01966441.6
   Entitled: “Methods and Compositions for Tissue Regeneration”

17. 17811-017-061 (M-17 WO)
   PCT Patent Application No. PCT/US01/27104
   Entitled: “Methods and Compositions for Tissue Regeneration”

18. 17811-028 (M-28)
    Entitled: “Fibrin Cell Supports and Methods of Use Thereof”

19. 17811-028-061 (M-28 WO)
    PCT Patent Application No. PCT/IB03/04506
    Entitled: “Fibrin Cell Supports and Methods of Use Thereof”
**FORM PTO-1595**  
(Rev. 6-93)  
OMB No. 0651-0011 (exp. 4/94)  

**U.S. DEPARTMENT OF COMMERCE**  
Patent and Trademark Office

---

**Please record the attached original documents or copy thereof.**

1. **Name of conveying party(ies):**  
   Epitech SA (executed 12/15/04)  
   Additional name(s) of conveying party(ies) attached?  
   2  Yes ☑  No

2. **Name and address of receiving party(ies):**  
   Name: DFB Pharmaceuticals, Inc.  
   Internal Address: 3909 Helen Street  
   Fort Worth, TX 76107  
   Secondary Address: (same as above)

Additional name(s) & address(es) attached?  
☑ Yes  ☑ No

3. **Nature of conveyance:**  
   ☑ Assignment  
   ☑ Security Agreement  
   ☑ Merger  
   ☑ Charge of Name

Additional numbers attached?  
☑ Yes  ☑ No

4. **Application number(s) or patent number(s):**  
   If this document is being filed together with a new application, the execution date of the application is ________

   **A. Patent Application No(s):**  
   SEE ATTACHED SCHEDULE A

   **B. Patent No(s):**  
   SEE ATTACHED SCHEDULE A

5. **Name and address of party to whom correspondence Concerning document should be mailed:**  
   Name: Ivor R. Elphitt, Ph.D.  
   Address: MINTZ, LEVIN, COHN, FERRIS GLOVSKY and POGOEO, P.C.  
   One Financial Center  
   Boston, MA 02111

6. **Total number of applications and patents involved:**  

7. **Total fee (37 CFR 3.41):**  
   $280.00  
   ☑ Enclosed  
   ☐ The Commissioner is authorized to charge Deposit Account  
   No: 55-0311, Reference No. 17811-915

---

**Statement and signature**  
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Christina K. Stock  
Reg. No. 45,889  
Name of Person Signing

Signature  
2/16/2005  
February 16, 2005

---

Mail documents to be recorded with required cover sheet information to:  
MAIL STOP ASSIGNMENT RECORDECATION SERVICES  
Director of the U.S. Patent and Trademark Office  
P.O. Box 1450, Alexandria, VA 22313-1450

---

**RECORDED: 09/21/2007**  
**REEL: 019864 FRAME: 0189**